Evidence map›Paper›PMID 32788725›Full record

ArticleNature2020

Serine restriction alters sphingolipid diversity to constrain tumour growth.

Thangaselvam Muthusamy, Thekla Cordes, Michal K Handzlik, Le You, Esther W Lim, Jivani Gengatharan, Antonio F M Pinto, Mehmet G Badur, Matthew J Kolar, Martina Wallace and 2 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 303 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Thangaselvam MuthusamyDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Thekla Cordes *Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Michal K Handzlik *Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4653-1902
Le You *Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Esther W LimDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Jivani GengatharanDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Antonio F M PintoMass Spectrometry Core, Salk Institute for Biological Studies, La Jolla, CA, USA.
Mehmet G BadurDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Matthew J KolarClayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8054-9121
Martina WallaceDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Alan SaghatelianClayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0427-563X
Christian M MetalloDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA. cmetallo@ucsd.edu.
University of California San Diego · USSalk Institute for Biological Studies · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3M
Research Education CoreU54CA132379 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARREDONDO, ELVA M, CROWE, SHEILA E. · 2008 to 2021
$16.1M
Training in Multi-Scale Analysis of Biological Structure and FunctionT32EB009380 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrew D. McCulloch, Padmini Rangamani · 2009 to 2026
$4.8M
Non-essential amino acids and sphingolipid diversity in cancer progressionR01CA234245 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2019 to 2023
$1.9M
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2R01CA188652 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2014 to 2018
$1.6M
Modeling and analysis of the mechanochemical processes that govern clathrin-mediated endocytosisR01GM132106 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RANGAMANI, PADMINI · 2020 to 2024
$1.5M
A Hybrid Quadrupole-Orbitrap LC/MSS10OD021815 · OD · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SAGHATELIAN, ALAN · 2016 to 2016
$580k
NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA188652NCI NIH HHS R01 CA234245NCI NIH HHS U54 CA132379NIBIB NIH HHS T32 EB009380NIGMS NIH HHS R01 GM132106NIGMS NIH HHS T32 GM007198NIH HHS S10 OD021815
6 · The paper itself

Abstract

Serine, glycine and other nonessential amino acids are critical for tumour progression, and strategies to limit their availability are emerging as potential therapies for cancer

Indexed as

AlanineAnimalsCell AdhesionCell DivisionDietFemaleGlycineHCT116 CellsHumansMembrane LipidsMiceMitochondriaNeoplasmsPhosphoglycerate DehydrogenasePyruvic AcidSerine1-deoxysphingolipidAlanineGlycineMembrane LipidsPhosphoglycerate DehydrogenasePyruvic AcidSerineSerine C-PalmitoyltransferaseSphingolipids

Identifiers

PMID32788725
PMCPMC7606299
OpenAlexW3048569636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.